argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-03-04 08:21 |
argenx to Present at Cowen and Company 39th Annual Health Care Conference
|
English | 28.3 KB | ||
| 2019-02-28 08:27 |
argenx reports fourth quarter business update and full year 2018 financial resu…
|
English | 112.0 KB | ||
| 2019-02-21 08:33 |
argenx to host conference call & webcast to report fourth quarter business upda…
|
English | 35.6 KB | ||
| 2019-02-04 08:18 |
argenx and Halozyme enter global collaboration and license agreement for ENHANZ…
|
English | 215.4 KB | ||
| 2019-01-21 08:32 |
argenx announces closing of exclusive global collaboration and license agreemen…
|
English | 332.9 KB | ||
| 2019-01-03 08:17 |
argenx to Present at 37th Annual J.P. Morgan Healthcare Conference
|
English | 28.5 KB | ||
| 2018-12-03 08:37 |
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Im…
|
English | 129.4 KB | ||
| 2018-12-03 08:37 |
argenx enters exclusive global collaboration and license agreement with Cilag G…
|
English | 53.3 KB | ||
| 2018-11-07 08:40 |
argenx to Present at Upcoming Investor Conferences
|
English | 17.6 KB | ||
| 2018-11-01 15:32 |
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in …
|
English | 49.1 KB | ||
| 2018-10-25 08:51 |
argenx reports third quarter 2018 financial results and provides business update
|
English | 111.3 KB | ||
| 2018-10-09 08:44 |
argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG te…
|
English | 330.1 KB | ||
| 2018-09-24 09:02 |
argenx announces closing of U.S. public offering for gross proceeds of approxim…
|
English | 16.7 KB | ||
| 2018-09-19 15:18 | English | 867.0 KB | |||
| 2018-09-19 08:04 |
argenx raises approximately $300.6 million in gross proceeds in a U.S. public o…
|
English | 159.9 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
